Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 84.96% | 5.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 84.96% | 5.50% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 84.96% | 5.50% | |||
| SG&A Expenses | -30.40% | -5.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.60% | -7.74% | |||
| Operating Income | 39.46% | 11.88% | |||
| Income Before Tax | -1.39% | 14.90% | |||
| Income Tax Expenses | 193.94% | 82.45% | |||
| Earnings from Continuing Operations | -1.57% | 14.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.57% | 14.60% | |||
| EBIT | 39.46% | 11.88% | |||
| EBITDA | 39.69% | 11.90% | |||
| EPS Basic | 5.19% | 36.50% | |||
| Normalized Basic EPS | 27.59% | 36.29% | |||
| EPS Diluted | 5.19% | 36.50% | |||
| Normalized Diluted EPS | 27.59% | 36.29% | |||
| Average Basic Shares Outstanding | 7.13% | 34.49% | |||
| Average Diluted Shares Outstanding | 7.13% | 34.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||